Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Moderna and China at Impasse over Selling mRNA COVID Vaccine in China

publication date: Oct 4, 2022

Moderna says it is “eager” to sell its mRNA Vaccine in China, but balks at the conditions China imposes: either Moderna must sign up with a China-based partner, transferring all its technology to the China company and allowing the China company to make the drug, or the company must build a China manufacturing facility, again with a China partner, which would not involve a technology transfer. Either way, Moderna assumes it would lose effective control of its IP, which it refuses to do, citing worries that its reputation would suffer if a partner produced unsafe/lower quality vaccines. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital